| VY® Morgan Stanley Global Franchise Portfolio | PORTFOLIO OF INVESTMENTS |
| as of September 30, 2022 (Unaudited) |
| Shares | Value | Percentage of Net Assets | ||||
| COMMON STOCK: 97.5% | ||||||
| France: 7.0% | ||||||
| 17,821 | L'Oreal S.A. | $ | 5,698,102 | 1.9 | ||
| 13,353 | LVMH Moet Hennessy Louis Vuitton SE | 7,872,562 | 2.7 | |||
| 39,557 | Pernod Ricard SA | 7,256,867 | 2.4 | |||
| 20,827,531 | 7.0 | |||||
| Germany: 4.4% | ||||||
| 162,411 | SAP SE | 13,235,661 | 4.4 | |||
| Italy: 0.4% | ||||||
| 126,618 | Davide Campari-Milano NV | 1,120,256 | 0.4 | |||
| Netherlands: 2.3% | ||||||
| 78,417 | Heineken NV | 6,848,215 | 2.3 | |||
| United Kingdom: 9.9% | ||||||
| 147,616 | Experian PLC | 4,321,084 | 1.4 | |||
| 274,373 | Reckitt Benckiser Group PLC | 18,185,772 | 6.1 | |||
| 59,182 | Relx PLC (EUR Exchange) | 1,442,401 | 0.5 | |||
| 225,958 | Relx PLC (GBP Exchange) | 5,521,428 | 1.9 | |||
| 29,470,685 | 9.9 | |||||
| United States: 73.5% | ||||||
| 117,053 | Abbott Laboratories | 11,326,048 | 3.8 | |||
| 56,818 | Accenture PLC | 14,619,271 | 4.9 | |||
| 39,786 | Automatic Data Processing, Inc. | 8,999,195 | 3.0 | |||
| 194,672 | Baxter International, Inc. | 10,485,034 | 3.5 | |||
| 45,973 | Becton Dickinson & Co. | 10,244,164 | 3.4 | |||
| 29,245 | Broadridge Financial Solutions, Inc. ADR | 4,220,638 | 1.4 | |||
| 97,869 | Coca-Cola Co. | 5,482,621 | 1.9 | |||
| 66,883 | Danaher Corp. | 17,275,210 | 5.8 | |||
| 29,378 | Equifax, Inc. | 5,036,271 | 1.7 | |||
| 18,420 | Estee Lauder Cos., Inc. | 3,976,878 | 1.3 | |||
| 80,510 | Fidelity National Information Services, Inc. | 6,084,141 | 2.1 | |||
| 126,528 | Intercontinental Exchange, Inc. | 11,431,805 | 3.8 | |||
| 115,636 | Microsoft Corp. | 26,931,624 | 9.0 | |||
| 12,399 | Moody's Corp. | 3,014,321 | 1.0 | |||
| 41,783 | Nike, Inc. - Class B | 3,473,003 | 1.2 | |||
| 68,687 | Otis Worldwide Corp. | 4,382,231 | 1.5 | |||
| 246,677 | Philip Morris International, Inc. | 20,476,658 | 6.9 | |||
| 64,238 | Procter & Gamble Co. | 8,110,048 | 2.7 | |||
| 18,873 | Roper Technologies, Inc. | 6,787,486 | 2.3 | |||
| 11,419 | STERIS Public Ltd. Co. | 1,898,751 | 0.6 | |||
| 27,679 | Thermo Fisher Scientific, Inc. | 14,038,512 | 4.7 | |||
| 98,493 | Visa, Inc. - Class A | 17,497,281 | 5.9 | |||
| 22,305 | Zoetis, Inc. | 3,307,608 | 1.1 | |||
| 219,098,799 | 73.5 | |||||
| Total Common Stock | ||||||
| (Cost $250,403,460) | 290,601,147 | 97.5 | ||||
| Shares | Value | Percentage of Net Assets | ||||
| SHORT-TERM INVESTMENTS: 1.4% | ||||||
| Mutual Funds: 1.4% | ||||||
| 4,262,908 | (1) | BlackRock Liquidity Funds, FedFund, Institutional Class, 2.760% | ||||
| (Cost $4,262,908) | 4,262,908 | 1.4 | ||||
| Total Short-Term Investments | ||||||
| (Cost $4,262,908) | 4,262,908 | 1.4 | ||||
| Total Investments in Securities (Cost $254,666,368) |
$ | 294,864,055 | 98.9 | |||
| Assets in Excess of Other Liabilities | 3,368,074 | 1.1 | ||||
| Net Assets | $ | 298,232,129 | 100.0 | |||
| ADR | American Depositary Receipt |
| (1) | Rate shown is the 7-day yield as of September 30, 2022. |
| Sector Diversification | Percentage of Net Assets | |||
| Information Technology | 33.0 | % | ||
| Consumer Staples | 25.9 | |||
| Health Care | 23.0 | |||
| Industrials | 6.9 | |||
| Financials | 4.9 | |||
| Consumer Discretionary | 3.8 | |||
| Short-Term Investments | 1.4 | |||
| Assets in Excess of Other Liabilities | 1.1 | |||
| Net Assets | 100.0 | % | ||
Portfolio holdings are subject to change daily.
| VY® Morgan Stanley Global Franchise Portfolio | PORTFOLIO OF INVESTMENTS |
| as of September 30, 2022 (Unaudited) (Continued) |
| Fair Value Measurements |
| The following is a summary of the fair valuations according to the inputs used as of September 30, 2022 in valuing the assets and liabilities: |
| Quoted Prices in Active Markets for Identical Investments (Level 1) | Significant Other Observable Inputs# (Level 2) | Significant Unobservable Inputs (Level 3) | Fair Value at September 30, 2022 | |||||||||||||
| Asset Table | ||||||||||||||||
| Investments, at fair value | ||||||||||||||||
| Common Stock | ||||||||||||||||
| France | $ | – | $ | 20,827,531 | $ | – | $ | 20,827,531 | ||||||||
| Germany | – | 13,235,661 | – | 13,235,661 | ||||||||||||
| Italy | – | 1,120,256 | – | 1,120,256 | ||||||||||||
| Netherlands | – | 6,848,215 | – | 6,848,215 | ||||||||||||
| United Kingdom | – | 29,470,685 | – | 29,470,685 | ||||||||||||
| United States | 219,098,799 | – | – | 219,098,799 | ||||||||||||
| Total Common Stock | 219,098,799 | 71,502,348 | – | 290,601,147 | ||||||||||||
| Short-Term Investments | 4,262,908 | – | – | 4,262,908 | ||||||||||||
| Total Investments, at fair value | $ | 223,361,707 | $ | 71,502,348 | $ | – | $ | 294,864,055 | ||||||||
| # | The earlier close of the foreign markets gives rise to the possibility that significant events, including broad market moves, may have occurred in the interim and may materially affect the value of those securities. To account for this, the Portfolio may frequently value many of its foreign equity securities using fair value prices based on third party vendor modeling tools to the extent available. Accordingly, a portion of the Portfolio's investments are categorized as Level 2 investments. |
At September 30, 2022, the aggregate cost of securities and other investments and the composition of unrealized appreciation and depreciation of securities and other investments on a tax basis were:
| Cost for federal income tax purposes was $255,659,937. | ||||||
| Net unrealized appreciation consisted of: | ||||||
| Gross Unrealized Appreciation | $ | 65,229,907 | ||||
| Gross Unrealized Depreciation | (26,021,052 | ) | ||||
| Net Unrealized Appreciation | $ | 39,208,855 | ||||